Independent Chairman, Tessara Therapeutics Pty Ltd
Stories naming Dr Greg Collier. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Tessara Therapeutics closed a $2.7 million oversubscribed Round 1 raise led by a New South Wales syndicate, appointed Phillip Smith to its board, and works with CSIRO and Bio-Link Australia.
Wholesale Investor profile of Tessara Therapeutics, a biotech developing 3D human brain tissue for drug discovery; recounts past grants, an R&D tax incentive, CSIRO partnership, board and revenue projections.
ChemGenex has signed a convertible note deal giving Cephalon up to A$15 million in notes, plus options over 19.9 percent of shares held by Stragen and Merck; major shareholders back the issue.
Also GBS Ventures
AusBiotech's release announces ChemGenex chief executive Greg Collier won the 2009 Chairman's Excellence Award for his contribution to Australian biotechnology, noting the company's US drug application for a leukemia medicine.
ChemGenex Pharmaceuticals has hired Thomas DeZao as senior vice president and chief commercial officer to lead US commercialisation of its leukemia drug omacetaxine; his past roles span Genitope, Corixa/Coulter, Asta Medica and Chiron.
ASX-listed drug developer ChemGenex will quit NASDAQ and SEC reporting to cut compliance costs, and three directors step down in July while staying on as advisers.
ChemGenex Pharmaceuticals reports pre-clinical findings that omacetaxine destroys leukemic stem cells in chronic myeloid leukemia models, presented at the European Hematology Association congress, with collaborators in Glasgow and a US leukemia specialist.
ChemGenex reported Phase 2/3 trial results for omacetaxine in resistant CML patients at ASCO, with investigators suggesting it could become the first workable therapy for T315I-mutant patients; regulatory filing targeted for Q3.
ChemGenex Pharmaceuticals has hired oncology drug developer Dr Adam Craig as its chief medical officer, its third senior clinical appointment lately, as it prepares its cancer drug omacetaxine for a regulatory filing.
A 2007 announcement that Australian biotech ChemGenex Pharmaceuticals appointed former Amgen executive Dr George Morstyn to its board, with CEO Greg Collier citing his oncology development and commercialisation expertise.
ChemGenex has begun enrolling patients in a second phase 2/3 trial testing Ceflatonin in chronic myeloid leukemia patients resistant to prior tyrosine kinase inhibitor treatment, with data expected in 2008.
ChemGenex completed an A$10.5m rights issue following an equal February institutional placement, a combined A$21m raise, with Alta Partners and GBS Venture Partners increasing their stakes to fund Ceflatonin leukemia trials.